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A startling change has occurred in the way medical products
and services are promoted to the public since I completed
house staff training. At that time it was unheard of for
prescription drugs or medical procedures to be advertised to
lay consumers. Rather, marketing and education efforts were
directed almost exclusively to physicians. As we enter 2003,
direct-to-consumer (DTC) advertising has been in place for
years and is growing steadily. Recently, the issue of DTC
promotion by pharmaceutical companies has been colored
by similar advertising to the public by physicians and
hospitals, and by new government rules addressing the
interaction of pharmaceutical companies with health care
professionals. Such advertising remains controversial and
stirs strong emotions in many quarters.
Currently, DTC advertising is permitted only in the U.S.
and New Zealand. The first DTC advertisement of a
prescription drug appeared in Reader’s Digest in 1981. In
1985 the Food and Drug Administration (FDA) permitted
DTC promotion providing it contained fair balance and full
disclosure. Although such standards could readily be met in
printed publications, albeit often in the fine print, they were
difficult to achieve in an image media such as television. The
watershed for video advertising came in 1997 when the
FDA decided that it was not necessary for specific infor-
mation regarding a drug, such as indications and side effects,
to be in the promotion if sources, such as telephone
numbers and Internet sites, were provided from which this
information could be obtained.
Since 1997 there has been a tremendous growth in DTC
advertising of brand name prescription drugs. Spending for
DTC advertising has increased from $600 million in 1996
to approximately $2.5 billion in the current year, and has
been projected to grow to $7.5 billion in the future.
Although most promotions target non–life-threatening dis-
orders, such as baldness or allergies, the full spectrum of
disease entities has been considered. Currently, it is virtually
impossible to watch television for even a short interval and
not see a commercial for a prescription drug.
The support for DTC advertising must, of course, be
drawn from some source, such as promotion to physicians.
In fact, Woloshin et al. (1) reported in the Lancet in 2001
that in the preceding year pharmaceutical companies had
spent $685 million on advertisements in newspapers and lay
magazines, compared to $473 million in medical journals.
Given the much smaller financial base of medical journals
than the lay press, this poses an issue of some concern to the
traditional vehicle used to transmit new research discoveries
and other educational material. However, it must be recog-
nized that DTC advertising still represents only a small part
of industrial expenditures for promotion. Data from
Rosenthal et al. (2) in the New England Journal of Medicine
found that DTC advertising accounts for only 15% of
money spent on drug promotion by industry, and is highly
concentrated in a subgroup of products.
The DTC advertisements are generally received favorably
by the public. People have reported that they feel that an
advertisement in the lay media conveys increased credibility
upon the product and its claims. In fact, many individuals
believe that a drug must be completely safe to be advertised
in a public venue such as television. Thus, far from being
viewed as unbalanced or self serving, drug advertisements
seem to imply a degree of efficacy and safety for the product
in the mind of the public.
It is clear that DTC advertising would not continue to
flourish if it were not successful. Although it is difficult to
measure the effect of DTC upon sales, some evidence can be
drawn from the available data. One national survey indi-
cated that two-thirds of Americans reported seeing at least
one advertisement for a prescription drug. Ten percent of
the surveyed individuals requested the drug from their
physician, a request which was honored approximately 70%
of the time. Another study found that approximately 80% of
cardiologists indicated that patients had requested a specific
prescription drug. The National Institute for Healthcare
Management reported that spending on prescription drugs
increased by $20.8 billion from 1999 to 2000, and nearly
48% of the increase was the result of sales of the 50 drugs
with the largest advertising budgets. The exact increase due
to advertising is, of course, uncertain.
The proponents of DTC advertising cite an impressive
list of potential benefits that may accrue from these promo-
tions. They point out that such promotion can teach
patients to recognize disease, encourage them to take
responsibility for their own health, and motivate them to
seek needed medical attention. Used properly, it is posited
that DTC can prompt an informed discussion between
patients and their physicians. Of importance, DTC repre-
sents one approach to avoid the well-documented under-
utilization of drugs of proven efficacy, including beta-
blockers and angiotensin-converting enzyme inhibitors.
Finally, advocates indicate that promotion to the public is
protected by the right to free speech, and that the informa-
tion provided is already widely available in lay publications
and on the Internet.
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In contrast to the above, in a recent survey by Lipsky et
al. (3) in the Journal of Family Practice, most physicians were
ambivalent or negative about DTC advertising. A number
of concerns have been expressed regarding promotion of
prescription drugs to the public. There is concern that such
commercials may “medicalize” trivial complaints, such as a
runny nose or occasional fatigue, or imply that drugs are the
answer to every symptom. Advertisements may certainly
increase the demand for pharmaceuticals, appropriately or
inappropriately, placing the physician in the difficult posi-
tion of risking patient alienation if the request is denied.
Filling prescriptions for unnecessary or marginally indicated
drugs, which are often the newest and most expensive
agents, has the potential to produce a large increase in
health care expenses. Of great concern is the potential of
DTC commercials to undermine the credibility of the
physician, and to imply that they are not providing adequate
care, particularly if drug requests are denied. Finally, a
potential worry exists that the promotions are not fully
balanced, and that the actual efficacy and side effects of the
drugs are not presented in detail. In fact, severe side effects
of new pharmacologic agents are often not identified until
post-marketing surveillance (e.g., troglitazone), so that use
of these drugs rather than older agents of proven value may
expose patients to increased risk.
The concerns regarding DTC advertising might be more
than offset by potential benefits, if they indeed exist.
However, no data are available regarding the ability of
promoting prescription drugs to the public to produce
favorable effects. There is neither evidence that DTC
advertising increases application of beneficial therapy, nor
that it enhances outcomes or reduces morbidity. Accord-
ingly, it is understandable that some parties question
whether considerable expense is being incurred for no
benefit. In fact, in 2001 the United Kingdom Consumers
Association, a prominent consumer group, opined that
DTC advertising had led to increased drug bills, distorted
prescribing behavior, and misinformation for patients.
It is interesting, if not ironic, that the increase in DTC
advertising in the last five years has been somewhat paral-
leled by similar marketing efforts by physicians and hospi-
tals. Physicians increasingly advertise services directly to the
public, while hospitals tout programs in services, such as
cardiac disease and cancer, as well as favorable performance
statistics. This trend is perhaps expressed to the greatest
extent by imaging centers that screen for early detection of
disease. In fact, even medical journals participate in this
process by providing press releases on selected reports from
each issue, often when the ultimate value of the new data is
completely speculative. It would seem reasonable that the
same demand for balance, completeness, and proof of
benefit be required of advertising by health care profession-
als as is required of pharmaceutical companies.
Another issue related to DTC advertising is the interac-
tion of the pharmaceutical industry with physicians and
other health care professionals involved in the provision of
drugs to patients. As this paper is submitted for press, the
Office of the Inspector General, Janet Rehnquist, has just
released new rules proscribing the offer of financial
incentives or other tangible benefits by pharmaceutical
companies provided to physicians, pharmacists, or others
who managed drug benefits. Such incentives were said to
include educational conferences and research grants to
doctors and hospitals. Given the importance that indus-
trial support has assumed in post-graduate education and
clinical research in contemporary medicine, the new rules
could have profound consequences that could ultimately
impact patient care.
The basis for the new rules was said to be concerned
about industry marketing practices that could improperly
drive up Medicare and Medicaid costs. The notice of the
rules will be posted in the Federal Register for comment by
more knowledgeable people than myself. However, as an
initial impression, it seems to be somewhat contradictory for
the FDA to foster DTC marketing while the Office of the
Inspector General undertakes action that may inhibit re-
search to define the optimal use of new drugs, and trans-
mission of this information to physicians charged with the
care of patients.
Many essays and editorials have previously addressed the
topic of the DTC advertising of prescription drugs. The
potential benefits and hazards of DTC advertising have
been well delineated. The debate regarding DTC advertis-
ing continues, and is often spirited. The one thing that
appears certain is that a pressing need exists to define the
benefits, if any, produced by DTC advertising. Such studies
should also assess any pitfalls, such as increased adverse drug
effects or deterioration of the physician-patient relationship.
Physicians and industry representatives should collaborate
in defining the best method to increase clinical application
of therapies which have proven to be of benefit and the best
technique to introduce newly discovered agents. Similar
studies are warranted with regard to marketing by physi-
cians and other health care providers. As evidence-based
physicians, it is only when we have accurate data regarding
the value of marketing prescription drugs and medical
services directly to the public that we can optimize the
process, or call for its limitation or termination.
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